SIGY and SIGYD Related Headlines
Go Back- Oragenics signs letter of intent to license blood purification technology
- Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
- Sigyn Therapeutics explores NASDAQ merger, establishes clinical pathway
- Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream
- Sigyn Therapeutics to Present at the Life Sciences Virtual Investor Forum on September 18th
- Life Science Virtual Investor Forum Agenda Announced for September 18th
- Sigyn Therapeutics adds Dr. Christoph Zaba to advisory board
SIGY and SIGYD Related Press Releases
Go Back- Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
- Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE
- Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases
- Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives
- Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
- The Emergence of Blood Purification Devices to Treat Cardiovascular Disease
- Sigyn CEO Note: First-In-Industry Attributes of CardioDialysisTM to Treat Cardiovascular Disease
- Sigyn CardioDialysis(TM) Featured on the Big Biz Show
- Sigyn Therapeutics Reports Third Quarter Financial Results and Subsequent Introduction of CardioDialysis(TM)
- Sigyn Therapeutics Releases Shareholder Letter to Introduce CardioDialysis(TM)
- Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream
- Sigyn Therapeutics to Present at the Life Sciences Virtual Investor Forum on September 18th
- Life Science Virtual Investor Forum Agenda Announced for September 18th
- Sigyn Therapeutics Appoints Dr. Christoph Zaba to Its Scientific Advisory Board
- Sigyn Therapeutics Announces Cardiovascular Disease Study
SIGY and SIGYD Related SEC Filings
Go Back- Form 8-K Sigyn Therapeutics, Inc. For: Feb 20
- Form SCHEDULE 13G/A Sigyn Therapeutics, Inc. Filed by: Brio Capital Master Fund Ltd.
- Form 10-Q Sigyn Therapeutics, Inc. For: Sep 30
- Form 10-Q Sigyn Therapeutics, Inc. For: Jun 30
- Form 8-K Sigyn Therapeutics, Inc. For: Aug 14
- Form NT 10-Q Sigyn Therapeutics, Inc. For: Jun 30
